M-083
Methylphenidate hydrochloride solution
(Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material, Cerilliant®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C14H20ClNO2
Numéro CAS:
Poids moléculaire :
269.77
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
certified reference material
Forme
liquid
Caractéristiques
Snap-N-Spike®/Snap-N-Shoot®
Conditionnement
ampule of 1 mL
Fabricant/nom de marque
Cerilliant®
drug control
Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)
Concentration
1.0 mg/mL in methanol (as free base)
Technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Application(s)
forensics and toxicology
Format
single component solution
Température de stockage
2-8°C
Chaîne SMILES
Cl.COC(=O)C(C1CCCCN1)c2ccccc2
InChI
1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H
Clé InChI
JUMYIBMBTDDLNG-UHFFFAOYSA-N
Informations sur le gène
human ... SLC6A2(6530) , SLC6A3(6531)
Description générale
Methylphenidate is a psychostimulant prescribed for treatment of attention-deficit hyperactivity disorder (ADHD), tachycardia and narcolepsy. This Certified Spiking Solution® is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology and forensic analysis. Methylphenidate is sold under trade names Concerta® and Ritalin®.
Application
- Methylphenidate HCl solution in ADHD pharmacotherapy studies: Research published in "Molecular Psychiatry" explored the effects of methylphenidate on Drosophila brain at single-cell resolution, highlighting its potential for ADHD treatment repurposing and its impact on neurotransmitter regulation (Qu et al., 2023).
- CNS stimulant research with high-purity methylphenidate HCl: A case study in "Children (Basel)" detailed the complex relationship between ADHD symptoms and self-induced weight loss in a child, underscoring methylphenidate′s role in managing hyperkinetic disorders and its potential interactions with eating behaviors (Mestermann et al., 2023).
- Neuropharmacology Methylphenidate in neurotransmitter research: A review in "Molecular Biotechnology" discussed the pharmacological applications of amino acids, using methodologies that could be applied to substances like methylphenidate for enhanced understanding of its interaction with brain chemistry and neurotransmitter functions (Kamaraj and Vuppu, 2023).
- Liquid methylphenidate for in vitro neuropharmacology studies: An analysis in "Journal of Medical Internet Research" investigated the nonmedical use and adverse effects of methylphenidate, providing insights into its impact during the COVID-19 pandemic and highlighting the importance of monitoring drug usage trends for improved public health strategies (Shin et al., 2023).
- Dopamine reuptake inhibitor research with methylphenidate solution: A report in "Journal of Analytical Toxicology" detailed a case of fatal intoxication where methylphenidate′s properties as a dopamine reuptake inhibitor were considered in the context of its toxicological profile, emphasizing the need for careful monitoring of its use and effects (Ameline et al., 2023).
Informations légales
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Concerta is a registered trademark of ALZA Corporation
Ritalin is a registered trademark of Novartis Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organes cibles
Eyes,Central nervous system
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
49.5 °F - closed cup
Point d'éclair (°C)
9.7 °C - closed cup
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Alice Charach et al.
Pediatrics, 131(5), e1584-e1604 (2013-04-03)
The US Agency for Healthcare Research and Quality sponsored a comparative effectiveness review of interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD). Medline, Cochrane CENTRAL, Embase, PsycInfo, and Education Resources Information Center were searched from 1980 to November 24
Evert J Semeijn et al.
Journal of the American Geriatrics Society, 61(6), 882-887 (2013-05-29)
To increase insight into the effect of attention-deficit/hyperactivity disorder (ADHD) on health in general in older adults. Two-phase sampling side-study. Longitudinal Aging Study Amsterdam (LASA). Two hundred twenty-three randomly selected LASA respondents. Information was collected during home visits on physical
Methylphenidate: trismus.
Prescrire international, 22(140), 185-185 (2013-08-21)
Eduardo Bruera et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2421-2427 (2013-05-22)
Cancer-related-fatigue (CRF) is common in advanced cancer. The primary objective of the study was to compare the effects of methylphenidate (MP) with those of placebo (PL) on CRF as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue
Liv Larsen Stray et al.
Behavioral and brain functions : BBF, 9, 18-18 (2013-05-07)
Most children who are diagnosed with attention deficit-hyperactivity disorder (ADHD) have moderate-to-severe motor problems using the Motor Function Neurological Assessment battery (MFNU). The MFNU focuses on specific muscle adjustment problems associated with ADHD, especially motor inhibition problems and high muscle
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique